Scholarlink

Purpose <p>To investigate the clinical features of patients with neuroendocrine tumors (NETs) who could not complete the standard protocol (4 cycles of 7.4&#xa0;GBq per 8&#xa0;weeks) <sup>177</sup>Lu-DOTATATE treatment<b>.</b></p> Materials and methods <p>A retrospective single-center analysis was conducted on 26 patients who underwent <sup>177</sup>Lu-DOTATATE treatment between December 2021 and August 2024. Therapeutic outcome was compared with clinical features, including location and number of metastatic lesions, interval from diagnosis to the first <sup>177</sup>Lu-DOTATATE treatment, and laboratory data. Statistical analyses were performed to identify clinical features associated with dose reduction or treatment discontinuation.</p> Results <p>The clinical data of 24 patients with metastatic neuroendocrine tumors (NETs) were analyzed, of whom 16 patients completed the standard protocol <sup>177</sup>Lu-DOTATATE treatment. The most common adverse events were hematologic toxicities. Eight patients did not complete the standard protocol treatment, primarily due to adverse events (6/8). Single variable logistic regression analysis revealed that the presence of somatostatin receptor scintigraphy (SRS) positive bone metastases (OR = 21.0, 95% CI 2.37–186, <i>p</i> = 0.006) and lower hemoglobin levels (OR = 0.479, 95% CI 0.255–0.900, <i>p</i> = 0.022) were significantly associated with incomplete treatment. Notably, 5/8 patients in the incomplete group had extensive bone metastases (&gt; 20 lesions), including 4 with diffuse metastases. Other variables, including age, sex, white blood cell count, platelet count, eGFR, and other metastatic sites, showed no significant association with treatment completion.</p> Conclusions <p>In this study, the presence of SRS-positive bone metastases and low hemoglobin levels were significant factors associated with the inability to complete <sup>177</sup>Lu-DOTATATE treatment for NET patients. Extensive bone metastases, such as diffuse metastasis or more than 20 bone metastases, may be particularly associated with the inability to administer standard protocol treatment.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Analysis of clinical factors associated with incomplete standard protocol 177Lu-DOTATATE treatment in neuroendocrine tumor patients

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年3月29日

查看全文
  • Shigeyasu Sugawara,
  • Shozo Okamoto,
  • Hirofumi Go,
  • Shiro Ishii,
  • Hiroshi Ito,
  • Tohru Shiga,
  • Noboru Oriuchi

摘要

Purpose

To investigate the clinical features of patients with neuroendocrine tumors (NETs) who could not complete the standard protocol (4 cycles of 7.4 GBq per 8 weeks) 177Lu-DOTATATE treatment.

Materials and methods

A retrospective single-center analysis was conducted on 26 patients who underwent 177Lu-DOTATATE treatment between December 2021 and August 2024. Therapeutic outcome was compared with clinical features, including location and number of metastatic lesions, interval from diagnosis to the first 177Lu-DOTATATE treatment, and laboratory data. Statistical analyses were performed to identify clinical features associated with dose reduction or treatment discontinuation.

Results

The clinical data of 24 patients with metastatic neuroendocrine tumors (NETs) were analyzed, of whom 16 patients completed the standard protocol 177Lu-DOTATATE treatment. The most common adverse events were hematologic toxicities. Eight patients did not complete the standard protocol treatment, primarily due to adverse events (6/8). Single variable logistic regression analysis revealed that the presence of somatostatin receptor scintigraphy (SRS) positive bone metastases (OR = 21.0, 95% CI 2.37–186, p = 0.006) and lower hemoglobin levels (OR = 0.479, 95% CI 0.255–0.900, p = 0.022) were significantly associated with incomplete treatment. Notably, 5/8 patients in the incomplete group had extensive bone metastases (> 20 lesions), including 4 with diffuse metastases. Other variables, including age, sex, white blood cell count, platelet count, eGFR, and other metastatic sites, showed no significant association with treatment completion.

Conclusions

In this study, the presence of SRS-positive bone metastases and low hemoglobin levels were significant factors associated with the inability to complete 177Lu-DOTATATE treatment for NET patients. Extensive bone metastases, such as diffuse metastasis or more than 20 bone metastases, may be particularly associated with the inability to administer standard protocol treatment.